Related Experiment Video
Updated: Sep 26, 2026
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Transforming growth factor-beta1 and renal cell cancer: cell growth, mRNA expression and protein production of
Tomoyuki Shimabukuro1, Yasukazu Ohmoto, Katsusuke Naito
1Department of Urology, Ube Industries Central Hospital, Ube, Japan.
Purpose:
We evaluated the effects of transforming growth factor-beta1 (TGF-beta1) on growth activity, cytokine mRNA expression and cytokine protein production by renal cancer cells.
Materials And Methods:
Exogenous continuous exposure of biologically active TGF-beta1 was performed on ACHN cells at various concentrations of 0.1 to 30 ng./ml. and the number of cells was counted each culture day. To determine the index of S-phase cells the bromodeoxyuridine pulse labeling method was used. Reverse transcriptase-polymerase chain reaction (PCR) was done and PCR products were quantified. Each supernatant cytokine level was measured using an enzyme-linked immunosorbent assay.
Results:
TGF-beta1 significantly inhibited the growth activities of ACHN cells compared with controls. Bromodeoxyuridine labeling indexes after treating ACHN cells with TGF-beta1 (10 ng./ml.) showed that it began to decrease gradually after 24 hours and after 72 hours it was inhibited to approximately 40% compared with controls. The mRNA of TGF-beta1, TGF-beta types 1 and 2 receptors, interleukin-6 (IL-6) and granulocyte-macrophage colony-stimulating factor (GM-CSF) from ACHN cells was detected by reverse transcriptase-PCR assay. IL-6 and GM-CSF proteins were produced constitutively from ACHN cells but other cytokines were not. Adding TGF-beta1 to the cell culture medium did not influence mRNA expression, or the protein production of IL-6 or GM-CSF.
Conclusions:
The inhibition of growth activities of ACHN cells by TGF-beta1 are mediated by its direct binding to specific receptors on ACHN cells followed by cell cycle inhibition, while TGF-beta1 seems to have no effect on the production of the cytokines studied.
Insights
Transforming growth factor-beta1 (TGF-beta1) inhibits renal cancer cell growth by affecting the cell cycle. TGF-beta1 does not alter the production of key cytokines like IL-6 and GM-CSF in these cells.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Renal cancer cell growth and cytokine production are critical factors in tumor progression.
- Transforming growth factor-beta1 (TGF-beta1) is a key regulator of cell growth and differentiation.
- Understanding TGF-beta1's role in renal cancer is essential for developing targeted therapies.
Purpose of the Study:
- To investigate the impact of TGF-beta1 on the growth activity of renal cancer cells (ACHN).
- To analyze the effects of TGF-beta1 on the mRNA expression and protein production of various cytokines in ACHN cells.
- To elucidate the mechanisms by which TGF-beta1 influences renal cancer cell behavior.
Main Methods:
- ACHN cells were exposed to varying concentrations of TGF-beta1.
- Cell growth was assessed by direct cell counting.
- Cell cycle S-phase activity was measured using bromodeoxyuridine pulse labeling.
- Cytokine mRNA expression was analyzed via reverse transcriptase-polymerase chain reaction (RT-PCR).
- Cytokine protein levels in cell supernatants were quantified using enzyme-linked immunosorbent assay (ELISA).
Main Results:
- TGF-beta1 significantly inhibited ACHN cell growth in a dose-dependent manner.
- Bromodeoxyuridine labeling indicated a gradual decrease in S-phase cells after TGF-beta1 treatment, reaching approximately 40% inhibition at 72 hours.
- mRNA for TGF-beta1, TGF-beta receptors, IL-6, and GM-CSF was detected in ACHN cells.
- IL-6 and GM-CSF were constitutively produced as proteins, but TGF-beta1 treatment did not alter their mRNA expression or protein levels.
Conclusions:
- TGF-beta1 inhibits renal cancer cell proliferation through direct binding to specific receptors, leading to cell cycle arrest.
- The observed growth inhibition is independent of TGF-beta1's effect on the production of IL-6 and GM-CSF.
- These findings highlight a specific mechanism of TGF-beta1 action in renal cancer, suggesting potential therapeutic targets.
Related Concept Videos
01:16TGF - β Signaling Pathway
02:38Mitogens and the Cell Cycle
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:24Regulation of Angiogenesis and Blood Supply
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:22PI3K/mTOR/AKT Signaling Pathway